In This Article
Last updated August 12, 2026 · Reviewed for research accuracy by the MarquePeptides technical team.
Overview of Incretin-Pathway Receptor Agonists
Semaglutide, Tirzepatide, and Retatrutide represent three successive generations of synthetic incretin-pathway receptor agonists, each expanding the number of receptor targets engaged simultaneously. Semaglutide is a single-receptor GLP-1 agonist; Tirzepatide is a dual GIP/GLP-1 co-agonist; Retatrutide is a triple agonist engaging GIP, GLP-1, and glucagon receptors. This progression is a useful case study in structure-activity research for multi-receptor peptide design.
Research context only: This article discusses receptor pharmacology and structural chemistry for laboratory research purposes. It does not describe dosing, administration, or use in humans. All three compounds are sold by MarquePeptides strictly for research use only.
Mechanism & Receptor Targeting
Semaglutide is a selective GLP-1 receptor agonist. Its fatty-diacid side chain promotes albumin binding, extending its plasma half-life relative to native GLP-1 — a design feature widely studied in half-life-extension peptide research.
Tirzepatide engages both the GIP and GLP-1 receptors from a single peptide backbone, a structural approach studied for its potential to combine two distinct incretin signaling pathways within one molecule.
Retatrutide extends this further by engaging GIP, GLP-1, and glucagon receptors. As the newest of the three, its structural and pharmacokinetic literature base is comparatively smaller, and researchers should treat published molecular data as provisional pending further peer-reviewed characterization.
Molecular Data Comparison
| Compound | CAS Number | Molecular Weight | Receptor Target(s) |
|---|---|---|---|
| Semaglutide | 910463-68-2 | 4113.58 g/mol | GLP-1 |
| Tirzepatide | 2023788-19-2 | 4813.45 g/mol | GIP / GLP-1 |
| Retatrutide | 2381089-84-3 | ≈4730.4 g/mol* | GIP / GLP-1 / Glucagon |
*Retatrutide’s published molecular weight varies slightly across early literature sources — confirm against your batch-specific mass spec report.
Research Applications by Compound
- Semaglutide — the most extensively characterized of the three; frequently used as a baseline reference compound in GLP-1 receptor binding assays.
- Tirzepatide — used in comparative studies examining dual-receptor engagement versus single-receptor agonism.
- Retatrutide — used in emerging research on triple-receptor co-agonism and glucagon-pathway interaction, an active area of ongoing publication.
Full product specifications, batch-specific COAs, and purity data for each compound are available on their respective product pages: Semaglutide, Tirzepatide, and Retatrutide.
References
- Lau J, et al. “Discovery of the Once-Weekly Glucagon-Like Peptide-1 Analog Semaglutide.” J Med Chem. 2015;58(18):7370-7380.
- Coskun T, et al. “LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist.” Mol Metab. 2018;18:3-14.
- Frias JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” N Engl J Med. 2021;385:503-515.
- Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514-526.
References provided for research context only. Products sold by MarquePeptides are For Research Use Only — not for human consumption.